Multidrug-Resistant Microbial Therapy Using Antimicrobial Peptides and the CRISPR/Cas9 System

Area of Science:

• Microbiology and Biotechnology
• Infectious Diseases
• Drug Discovery

Background:

• Multidrug-resistant (MDR) microbes pose a global health threat, leading to increased morbidity, mortality, and economic losses.
• Conventional antimicrobial therapies are becoming less effective against MDR organisms, necessitating the exploration of alternative treatments.

Purpose of the Study:

• To review the roles of antimicrobial peptides (AMPs) and the CRISPR-Cas9 system in combating MDR microbial infections.
• To discuss the limitations and future prospects of AMPs and CRISPR-Cas9 in clinical applications.

Main Methods:

• Literature review focusing on studies investigating antimicrobial peptides and CRISPR-Cas9 system.
• Analysis of mechanisms of action, efficacy against MDR pathogens (e.g., ESKAPE), and limitations of both therapeutic approaches.

Main Results:

• Antimicrobial peptides and CRISPR-Cas9 have demonstrated success in treating infections caused by MDR pathogens, including ESKAPE pathogens.
• Both strategies offer distinct mechanisms for microbial elimination or immune modulation.
• Identified limitations include potential toxicity, instability, and high manufacturing costs for both AMPs and CRISPR-Cas9.

Conclusions:

• Antimicrobial peptides and CRISPR-Cas9 represent promising alternatives to conventional antibiotics for MDR infections.
• Addressing current limitations is crucial for the successful clinical translation of these novel antimicrobial strategies.